Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
Intravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for treating bladder cancer for 3 decades. However, BCG therapy is ineffective in approximately 30–40% of cases. Since evidence supports the T helper type 1 (Th1) response to be essential in BCG-induced tum...
Saved in:
Main Authors: | Yi Luo, Jonathan Henning, Michael A. O'Donnell |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2011/728930 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mycobacterium bovis Bacillus Calmette-Guérin-Induced Macrophage Cytotoxicity against Bladder Cancer Cells
by: Yi Luo, et al.
Published: (2010-01-01) -
Immune responses of cattle vaccinated by various routes with Mycobacterium bovis Bacillus Calmette-Guérin (BCG)
by: Mitchell V. Palmer, et al.
Published: (2025-01-01) -
Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer
by: Mohammad Alghafees, et al.
Published: (2025-01-01) -
Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin (BCG)
by: Eric Gomez, et al.
Published: (2009-01-01) -
Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
by: Luís Lima, et al.
Published: (2012-01-01)